Company declares cash dividend of $0.05 per share
In Silico Metabolite Prediction Using Artificial Neural Network Ensembles
Drug metabolism plays a crucial role in understanding bioavailability and drug-drug interactions, as well as in the design of prodrugs and in avoiding undesirable toxic metabolites.
Circadian Variations in Exsorptive Transport: In Situ Intestinal Perfusion Data and In Vivo Relevance
The circadian timing system (CTS) governs the 24-h rhythm of the organism and, hence, also main pathways responsible for drug pharmacokinetics.
Simulations Plus Announces Further Success in Malaria Drug Design Project
Activity Seen Against Both Drug-Sensitive and Drug-Resistant Strains
Simulations Plus Reports Second Quarter and First Six Months FY2012 Financial Results
Net sales increase 6.4% to record for any quarter of $2.789 million; first half net income up 22.7% to $1.810 million
Simulations Plus Sets Date for 2nd Quarter 2012 Earnings Release and Conference Call
Conference Call to Be on Tuesday, April 10, at 4:15 PM ET
Simulations Plus Announces Preliminary Success in Malaria Drug Design Project
New Molecule Has Excellent Activity Against Malaria Parasite
Modeling of Furosemide in DILIsym™ Model Reveals Testable Hypotheses about Hepatotoxicity Mechanisms
A predictive, quantitative, mathematical model (DILIsym™) is under development as a public-private initiative based on the physiological processes involved in drug-induced liver injury. The model includes…
Simulations Plus Buys out Royalty Agreement
Company Now Owns IP in ADMET Predictor™ Enslein Metabolism Module
In Silico Modeling for the Nonlinear Absorption Kinetics of UK-343,664: A P-gp and CYP3A4 Substrate
The aim of this work was to extrapolate in vitro and preclinical animal data to simulate the pharmacokinetic parameters of UK-343,664, a P-glycoprotein (P-gp) and CYP3A4 substrate, in human.
Simulations Plus Reports Record Second Quarter FY2012 Preliminary Revenues
Net sales increase to new record for any quarter of $2.789 million, up 24% sequentially and 6.4% compared to 2QFY11
Simulations Plus Announces Changes in Board of Directors
Dr. David Ralph, Professor of Marketing at Pepperdine University, to Replace Dr. Richard Weiss, Retiring after Nearly 15 Years on Board
Small-molecule inhibitors of the androgen receptor
The present invention provides a method of inhibiting an androgen receptor by administering a compound of Formula I: or a compound of Formula II: wherein R1, R2, R3 and...
Provisional Biopharmaceutical Classification of Some Common Herbs Used in Western Medicine
The aim of this study was to classify some markers of common herbs used in Western medicine according to the Biopharmaceutical Classification System (BCS).
Simulations Plus Announces Cash Dividend
Board of directors declares an ongoing quarterly dividend of $0.05 per share
Simulations Plus Reports First Quarter FY2012 Financial Results
Net sales increase 9.6% to first quarter record $2.248 million; Net income up 30.9% to $755,000
Simulations Plus Sets Date for 1st Quarter 2012 Earnings Release and Conference Call
Conference Call to be on Wednesday, January 18, at 4:15 PM ET
Finally, a User-Friendly Way of Computing and Presenting Individual Group Contributions to Polyprotic Ionization of Drugs
It is tempting to “assign” the macroscopic ionization constants (apparent pKa ‘s obtained from titration experiments) of molecules to specific ionizable groups; however, this is strictly appropriate only…
Simulations Plus to Present at the Sidoti & Company, LLC Semi-Annual New York Micro-Cap Conference
Leader in Drug Discovery and Development Simulation and Modeling Software to Present on January 9, 2012; Sidoti NY Micro Cap Conference 2012